EoCene Ltd. has taken a significant step in its commercialization efforts by announcing its first European sales and distribution agreement for the CG-100 device. The agreement, made with Hospital Line SA, grants exclusive rights to market, sell, and distribute the CG-100 in Greece and Cyprus. This development is crucial for EoCene as it seeks to expand its market presence in the competitive pharmaceutical preparations sector.

The CG-100 device is designed to address challenges in colorectal surgery, providing a potential alternative to diverting stomas. EoCene's President and CEO, Allen Baharaff, emphasized the importance of this agreement, stating, “Signing our first European commercial distribution agreement represents an important milestone for Colospan.” The planned launch in Greece and Cyprus is expected to coincide with ongoing clinical studies in the U.S., further highlighting the device's potential.

Background

EoCene Ltd., traded on Nasdaq under the ticker EOCN, is a company focused on gastrointestinal disease management and innovative solutions in the pharmaceutical preparations sector. The company has recently undergone significant developments, including its previous name change from Galmed Pharmaceuticals Ltd. and its ongoing commitment to advancing medical technologies.

What the Filing Says

The recent filing, dated November 10, 2026, details the distribution agreement with Hospital Line SA, stating that “Hospital Line has been granted exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus.” This agreement is intended to serve as a foundation for further commercial expansion into additional European markets.

Impact

This agreement may significantly affect EoCene's growth trajectory as it seeks to penetrate European markets. By partnering with Hospital Line, a distributor with established relationships in the medical device sector, EoCene aims to enhance its competitive position. The collaboration is expected to improve market access for the CG-100 device and potentially lead to the introduction of additional Colospan products in the future.

What's Next

The filing does not say what happens next, but the anticipated commercial launch of CG-100 in Greece and Cyprus is expected to proceed alongside ongoing clinical studies in the U.S. This strategic move could pave the way for future agreements and expansions in other European markets.